Show simple item record

dc.contributor.authorAckermann, Christoph J
dc.contributor.authorReck, M
dc.contributor.authorPaz-Ares, L
dc.contributor.authorBarlesi, F
dc.contributor.authorCalifano, Raffaele
dc.date.accessioned2019-09-11T09:09:22Z
dc.date.available2019-09-11T09:09:22Z
dc.date.issued2019en
dc.identifier.citationAckermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: travelling at the speed of light. Lung Cancer. 2019;134:245-53.en
dc.identifier.pmid31319988en
dc.identifier.doi10.1016/j.lungcan.2019.06.007en
dc.identifier.urihttp://hdl.handle.net/10541/622063
dc.description.abstractThe development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.lungcan.2019.06.007en
dc.titleFirst-line immune checkpoint blockade for advanced non-small-cell lung cancer: travelling at the speed of lighten
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdomen
dc.identifier.journalLung Canceren
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record